My main research interest is in therapeutic applications of CRISPR-Cas systems for human genome editing. We aim to developp novel approaches to correct defective genes and reprogram liver cells so that they can produce the proteins missing in certain metabolic diseases metabolic diseases such as hereditary tyrosinemia type I and lysosomal storage diseases.

We also aim to employ the inherent fidelity of the Cas9 proteins from Streptococcus thermophilus to efficiently and specifically correct pathogenic mutations responsible for genetic liver diseases.

The talk I will be giving at the CERMO-FC seminar will take place from 14-14:15 pm on November 23, and I'm looking forward to sharing our work!

For any question or comment: jean-francois.rivest.2@ulaval.ca